Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degradar, in Healthy Post-Menopausal Women

Maureen G. Conlan¹ · Erik F. J. de Vries² · AWJM Glaudemans² · Yamei Wang³ · Steven Troy⁴

Published online: 30 August 2020
© The Author(s) 2020

Correction to:

European Journal of Drug Metabolism and Pharmacokinetics

<https://doi.org/10.1007/s13318-020-00635-3>

Authors would like to correct the errors in table 2. Corrected version of Table 2 given below.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s13318-020-00635-3>.

✉ Maureen G. Conlan
mconlan@radiuspharm.com

¹ Department of Oncology Clinical Development, Radius Health, Inc., 950 Winter Street, Waltham, MA 02451, USA

² Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

³ Department of Biostatistics, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA

⁴ Department of Clinical Pharmacology, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA

Table 2 Pharmacokinetic parameters of elacestrant in Study 001 and Study 004

Study 001							
SAD part ^a	$C_{\max}$ (ng/ml)	$t_{\max}$ (h)	$AUC_{0-\text{last}}$ (ng·h/ml)	$AUC_{0-\infty}$ (ng·h/ml)	$t_{1/2}$ (h)	CL/F (l/h)	V_z/F (l)
1 mg IV ($n=5$)	69.8±30.7	0.04±0.02	23.9±3.6	28.0±5.2	33.4±6.2	36.8±7.7 ^d	1730±155 ^e
1 mg ($n=2$) ^b	0.06±0.02	2.63±2.65	NR	NR	NR	NR	NR
10 mg ($n=6$)	0.7±0.4	1.92±1.28	13.1±9.4	16.8±11.7	31.9±8.1	760±323	33,700±13,800
25 mg ($n=6$)	1.8±0.5	1.64±1.42	32.2±15.7	40.6±21.6	32.5±6.0	786±419	34,500±13,300
50 mg ($n=6$)	3.4±0.7	1.92±2.03	61.3±11.7	73.3±13.2	29.1±3.4	702±134	29,800±8910
50 mg fed ($n=6$)	7.0±1.5	4.17±1.33	96.8±20.0	116±26.9	28.8±2.7	451±111	18,500±3050
100 mg ($n=6$)	11.8±2.0	2.58±1.72	247±71.9	294±80.8	28.4±3.9	361±92	14,900±4920
200 mg ($n=6$)	31.5±5.6	3.25±1.57	649±183	774±239	27.4±3.7	281±90	10,800±2860
MAD part ^a	$C_{\max}$ (ng/ml)	$t_{\max}$ (h)	$AUC_{0-\tau}$ (ng·h/ml)	R_{ac}	$t_{1/2}$ (h)	CL_{ss}/F (l/h)	V_z/F (l)
10 mg/day ($n=7$)—day 1	0.5±0.1	2.25±2.24	5.6±2.0				
Day 7	0.8±0.2	0.97±0.27	10.8±3.7	1.95±0.29	37.9±4.7	1020±347	54,600±15,100
25 mg/day ($n=7$) ^c —day 1	1.5±0.5	2.92±3.50	16.0±4.1				
Day 7	2.6±0.8	1.29±0.47	35.3±13.9	2.20±0.68	41.1±12.7	799±281	47,100±21,100
50 mg/day ($n=8$)—day 1	4.5±1.0	1.72±0.84	45.2±12.8				
Day 7	5.7±1.2	2.78±2.47	82.1±17.3	1.86±0.27	31.1±6.8	634±139	28,300±7750
100 mg/day ($n=8$)—day 1	10.4±2.8	3.93±3.01	122±55.6				
Day 7	20.5±7.7	2.50±1.10	265±118	2.18±0.37	35.5±8.2	437±166	22,500±10,100
200 mg/day ($n=8$)—day 1	27.3±6.8	2.94±1.47	284±64.8				
Day 7	43.5±10.8	3.31±1.58	627±164	2.22±0.27	47.3±24.9	339±90.4	23,200±13,200
Study 004							
200 mg/day ($n=15$)—day 7	51.6±14.5	3.41±1.18	695±200		38.6±5.3		
500 mg/day ($n=11$)—day 7	209±72.7	4.46±1.57	3140±1195		37.5±2.8		
750 mg/day ($n=6$)—day 7	328±68.6	3.33±0.52	4810±1522		38.6±4.1		
1000 mg/day ($n=3$)—day 7	543±60.5	4.33±1.53	8327±911		41.6±5.9		

All values reported as arithmetic means ± standard deviation (SD)

SAD single ascending dose, MAD multiple ascending dose, NR no result, $C_{\max}$ maximum concentration, AUC area under the concentration-time curve, $t_{1/2}$ half-life, V_z/F volume of distribution, R_{ac} accumulation ratio, CL/F clearance, $t_{\max}$ time to reach maximum concentration, ss steady state

^aStudy drugs were administered in the fasted condition unless otherwise indicated

^bOne subject was excluded from descriptive statistics due to emesis after dosing

^cOne subject was excluded from descriptive statistics on Day 1 due to emesis after dosing

^dCL

^e V_z